australian tga status of cjc-1295 dac and ipamorelin Pure Form Peptides — Research Peptides Australia CJC-1295 + Ipamorelin 5mg Stack

PMCID: PMC4863553

Monitoring Schedule Serum IGF-1 at baseline and at 8-12 weeks Fasting glucose at baseline and every 3-6 months (GH increases insulin resistance acutely) Thyroid panel at baseline (hypothyroidism blunts IGF-1 response) Blood pressure and fluid retention assessment at each visit The American Association of Clinical Endocrinology (AACE) recommends IGF-1 be kept within the age- and sex-adjusted reference range during any GH-stimulating therapy to minimize risk of adverse effects including fluid retention and glucose intolerance [9]

(2006) and Ionescu and Frohman (2006) in the Journal of Clinical Endocrinology and Metabolism

The analytical data obtained were found to be consistent with the previous literature 12